[go: up one dir, main page]

LT2013018A - Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus - Google Patents

Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus

Info

Publication number
LT2013018A
LT2013018A LT2013018A LT2013018A LT2013018A LT 2013018 A LT2013018 A LT 2013018A LT 2013018 A LT2013018 A LT 2013018A LT 2013018 A LT2013018 A LT 2013018A LT 2013018 A LT2013018 A LT 2013018A
Authority
LT
Lithuania
Prior art keywords
pharmaceutical composition
metabolic disorders
treating diabetes
diabetes
activated potentiated
Prior art date
Application number
LT2013018A
Other languages
English (en)
Other versions
LT5980B (lt
Inventor
Iljiich Oleg Epshtein
Original Assignee
Epshtein Iliich Oleg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44899155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2013018(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010130348/15A external-priority patent/RU2531048C2/ru
Priority claimed from RU2011127051/15A external-priority patent/RU2509572C2/ru
Application filed by Epshtein Iliich Oleg filed Critical Epshtein Iliich Oleg
Publication of LT2013018A publication Critical patent/LT2013018A/lt
Publication of LT5980B publication Critical patent/LT5980B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Išradimas skirtas farmacinei kompozicijai, akirtai panaudoti paciento, sergančio diabetu ar kitais metaboliniais sutrikimais, gydymui, kompozicija apima a) aktyvuotą-potencijuotą antikūno žmogaus insulino receptoriui formą ir b) aktyvuotą-potencijuotą antikūno endotelinei NO-sintazei formą.
LT2013018A 2010-07-21 2013-02-19 Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus LT5980B (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010130348/15A RU2531048C2 (ru) 2010-07-21 2010-07-21 Лекарственное средство для уменьшения резистентности к инсулину и лечения сахарного диабета и способ повышения эффективности лечения сахарного диабета инсулином и/или гипогликемическими препаратами
RU2011127051/15A RU2509572C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для уменьшения резистентности к инсулину и для лечения сахарного диабета, способ уменьшения резистентности к инсулину, способ лечения сахарного диабета и способ лечения сахарного диабета инсулином и/или гипогликемическими препаратами

Publications (2)

Publication Number Publication Date
LT2013018A true LT2013018A (lt) 2013-10-25
LT5980B LT5980B (lt) 2013-12-27

Family

ID=44899155

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2013018A LT5980B (lt) 2010-07-21 2013-02-19 Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus

Country Status (30)

Country Link
US (1) US8617555B2 (lt)
EP (2) EP2595658A2 (lt)
JP (2) JP2013533268A (lt)
KR (2) KR20130103486A (lt)
CN (1) CN103118707A (lt)
AR (1) AR082312A1 (lt)
AU (1) AU2011281240B2 (lt)
BR (1) BR112013001299A2 (lt)
CA (1) CA2805961A1 (lt)
CL (1) CL2013000200A1 (lt)
CZ (1) CZ2013124A3 (lt)
DE (1) DE112011102396T5 (lt)
DK (1) DK201370089A (lt)
EA (1) EA029847B1 (lt)
EE (1) EE05761B1 (lt)
ES (1) ES2445846R1 (lt)
FI (1) FI20135152L (lt)
FR (1) FR2962913A1 (lt)
GB (2) GB2496799B (lt)
IT (1) ITTO20110627A1 (lt)
LT (1) LT5980B (lt)
MX (1) MX2013000804A (lt)
MY (1) MY160979A (lt)
NO (1) NO20130265A1 (lt)
NZ (1) NZ606964A (lt)
PE (1) PE20130815A1 (lt)
PH (1) PH12013500140A1 (lt)
SE (1) SE1350212A1 (lt)
SG (1) SG187578A1 (lt)
WO (1) WO2012010966A2 (lt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
BRPI0712540A2 (pt) * 2006-06-06 2012-10-16 Oleg Iliich Epshtein agente medicinal para tratar adiposidade, diabetes, e doenças associadas com intoleráncia a glicose
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
PH12013500109A1 (en) 2010-07-15 2015-07-03 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
CA2804967A1 (en) * 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
ITTO20110638A1 (it) 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizione farmaceutica di combinazione e metodi per trattare patologie o stati patologici associati a patologie o stati patologici respiratori
DE112011102397T5 (de) * 2010-07-21 2013-05-08 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie
CA2805963A1 (en) 2010-07-21 2012-01-26 Oleg Iliich Epshtein A method of treating attention deficit hyperactivity disorder
SG10201403870XA (en) * 2010-08-06 2014-08-28 Oleg Iliich Epshtein Combination Pharmaceutical Composition And Methods Of Treating And Preventing The Infectious Diseases
TWI588153B (zh) * 2012-05-18 2017-06-21 中國醫藥大學 多胜肽、編碼該多胜肽之核酸分子、以及該多胜肽之應用
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US6150500A (en) * 1996-07-12 2000-11-21 Salerno; John C. Activators of endothelial nitric oxide synthase
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6933272B1 (en) * 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
CA2733212C (en) * 2002-08-22 2014-01-07 Nutrition 21, Inc. Arginine silicate inositol complex and use thereof
AU2004222357C1 (en) 2003-03-14 2009-11-19 Nutrition Research, Inc. Homeopathic formulations useful for treating pain and/or inflammation
WO2005067928A1 (en) * 2004-01-20 2005-07-28 Astellas Pharma Inc. Method for treating erectile dysfunction
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
BRPI0712540A2 (pt) * 2006-06-06 2012-10-16 Oleg Iliich Epshtein agente medicinal para tratar adiposidade, diabetes, e doenças associadas com intoleráncia a glicose
GB0812019D0 (en) * 2008-07-02 2008-08-06 Asterion Ltd Insulin
WO2012007845A2 (en) * 2010-07-15 2012-01-19 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
CA2804967A1 (en) * 2010-07-15 2012-02-09 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
PH12013500109A1 (en) * 2010-07-15 2015-07-03 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment
DE112011102397T5 (de) * 2010-07-21 2013-05-08 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzungen und Verfahren zur Behandlung von Schwindel, Kinetose und vegetativ-vaskulärer Dystonie
ITTO20110638A1 (it) * 2010-07-21 2012-01-22 Oleg Iliich Epshtein Composizione farmaceutica di combinazione e metodi per trattare patologie o stati patologici associati a patologie o stati patologici respiratori

Also Published As

Publication number Publication date
GB2496799A (en) 2013-05-22
DE112011102396T5 (de) 2013-05-02
JP2013533268A (ja) 2013-08-22
PE20130815A1 (es) 2013-07-18
EA029847B1 (ru) 2018-05-31
GB201707872D0 (en) 2017-06-28
AR082312A1 (es) 2012-11-28
ES2445846R1 (es) 2015-01-02
ITTO20110627A1 (it) 2012-01-22
US8617555B2 (en) 2013-12-31
WO2012010966A3 (en) 2012-03-29
PH12013500140A1 (en) 2013-03-11
AU2011281240B2 (en) 2016-07-07
GB2496799B (en) 2017-11-22
EA201300124A1 (ru) 2013-12-30
SE1350212A1 (sv) 2013-04-22
EP3693018A1 (en) 2020-08-12
BR112013001299A2 (pt) 2017-11-21
SG187578A1 (en) 2013-03-28
EE05761B1 (et) 2016-03-15
NZ606964A (en) 2015-08-28
ES2445846A2 (es) 2014-03-05
FI20135152A7 (fi) 2013-02-21
JP2016222684A (ja) 2016-12-28
EP2595658A2 (en) 2013-05-29
CN103118707A (zh) 2013-05-22
WO2012010966A2 (en) 2012-01-26
KR20130103486A (ko) 2013-09-23
AU2011281240A1 (en) 2013-03-07
US20130064824A1 (en) 2013-03-14
EE201300007A (et) 2013-08-15
GB2552405B (en) 2018-05-30
LT5980B (lt) 2013-12-27
CA2805961A1 (en) 2012-01-26
MX2013000804A (es) 2013-10-28
DK201370089A (en) 2013-02-19
CL2013000200A1 (es) 2015-01-23
MY160979A (en) 2017-03-31
CZ2013124A3 (cs) 2013-06-12
GB201302924D0 (en) 2013-04-03
FI20135152L (fi) 2013-02-21
KR20180127515A (ko) 2018-11-28
NO20130265A1 (no) 2013-04-18
FR2962913A1 (fr) 2012-01-27
GB2552405A (en) 2018-01-24

Similar Documents

Publication Publication Date Title
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
EA201401028A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения
MX2015008114A (es) Derivados de exendina-4.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
PH12015500688A1 (en) Exendin-4 derivatives as dual glp1/glucagon agonists
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2013186240A3 (en) Exendin-4 peptide analogues
PL3517539T3 (pl) Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II
FI20135146A7 (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
IN2012DN06309A (lt)
UA112981C2 (uk) Варіант людського gdnf
WO2012004416A3 (en) Treatment of a disease associated with retinal degenerative disorder
PL2852400T3 (pl) Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym, zastosowanie analogu insuliny, sposób dawkowania oraz sposób leczenia cukrzycy
EA202090141A1 (ru) Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
UA44184U (ru) Способ фармакоэкономического анализа технологий лечения при метаболическом синдроме
IT1398458B1 (it) Ago medicale per iniezioni, prelievi e/o punture
UA114792C2 (uk) Коагоніст глюкагонового рецептора/glp-1-рецептора
HK1194307A1 (en) Lixisenatide and metformin for treatment of diabetes type 2

Legal Events

Date Code Title Description
BB1A Patent application published

Effective date: 20131025

FG9A Patent granted

Effective date: 20131227

MM9A Lapsed patents

Effective date: 20190715